Publications by authors named "QingHeng Meng"
Xeligekimab, a recombinant fully human IgG4 monoclonal antibody, has been strategically developed to target IL-17A and is presently in the developmental phase for treating moderate to severe plaque psoriasis. This study aims to investigate the pharmacokinetic profile of Xeligekimab, utilizing data derived from clinical trials specifically conducted in Chinese patients. The study conducted a population pharmacokinetic (PopPK) analysis involving 614 patients with plaque psoriasis.
View Article and Find Full Text PDFArticle Synopsis
- The increasing use of electronic data management (EDC) is transforming how clinical trial data is handled.
- A study analyzed 20 clinical trials with over 5,400 subjects across 321 sites to assess EDC's benefits.
- Findings highlight improvements in data collection, cleaning, quality control, and decision-making in clinical trials, supporting further EDC adoption.
Fifty-two fungal isolates obtained from seawater were screened for anti-nematode activity. One isolate, an Acremonium sp., exhibited the highest activity against the pinewood nematode, Bursaphelenchus xylophilus.
View Article and Find Full Text PDF